ReviewInternational journal of nanomedicine2019
Smart nanomedicine agents for cancer, triggered by pH, glutathione, H
Review in International journal of nanomedicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- Chemotherapeutic Potential of Fluorouracil-Platinum (IV) Prodrugs Against Cisplatin-Resistant Colorectal Cancer Cells.Chemistry (Weinheim an der Bergstrasse, Germany) · 2026Article
- Advances in programmable DNA nanostructures enabling stimuli-responsive drug delivery and multimodal biosensing.RSC chemical biology · 2025Review
- Tumor-targeted multifunctional extracellular vesicles as drug carriers for lung cancer therapy.Extracellular vesicles and circulating nucleic acids · 2025Article
- Strategies for Pancreatic Cancer-Responsive Nanodrug Platforms Targeting Tumor Hypoxic Environments.International journal of nanomedicine · 2025Review
- Chemotherapeutic Potential of Chlorambucil-Platinum(IV) Prodrugs against Cisplatin-Resistant Colorectal Cancer Cells.International journal of molecular sciences · 2024Article
- Anticancer Effect of PtCancers · 2024Article
- Chemodynamic Therapy of Glioblastoma Multiforme and Perspectives.Pharmaceutics · 2024Review
- Tumor Microenvironment-Responsive 6-Mercaptopurine-Releasing Injectable Hydrogel for Colon Cancer Treatment.Gels (Basel, Switzerland) · 2023Article
- Smart nanomaterials for cancer diagnosis and treatment.Nano convergence · 2022Review
- Progress and Hurdles of Therapeutic Nanosystems against Cancer.Pharmaceutics · 2022Review
- Nanotechnology Advances in the Detection and Treatment of Cancer: An Overview.Nanotheranostics · 2022Review
- Prevent or Cure-The Unprecedented Need for Self-Reporting Materials.Angewandte Chemie (International ed. in English) · 2021Review
- The past, present, and future of breast cancer models for nanomedicine development.Advanced drug delivery reviews · 2021Review
- Combination Delivery of Alpha-Tocopheryl Succinate and Curcumin Using a GSH-Sensitive Micelle (PAH-SS-PLGA) to Treat Pancreatic Cancer.Pharmaceutics · 2020Article
- Recent Advances in Tumor Microenvironment Hydrogen Peroxide-Responsive Materials for Cancer Photodynamic Therapy.Nano-micro letters · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Effective tumor diagnosis and therapy have always been a significant but challenging issue. Although nanomedicine has shown great potential for improving the outcomes of tumor diagnosis and therapy, the nonspecial targeted distribution of nanomedicine agents in the whole body causes a low diagnosis signal-to-noise ratio and a potential risk of systemic toxicity. Recently, the development of smart nanomedicine agents with diagnosis and therapy functions that can only be activated by the tumor microenvironment (TME) is regarded as an effective strategy to improve the theranostic sensitivity and selectivity, as well as reduce the potential side effects during treatment. This article will introduce and summarize the latest achievements in the design and fabrication of TME-responsive smart nanomedicine agents, and highlight their prospects for enhancing tumor diagnosis and therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.